JP2019532931A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532931A5
JP2019532931A5 JP2019515654A JP2019515654A JP2019532931A5 JP 2019532931 A5 JP2019532931 A5 JP 2019532931A5 JP 2019515654 A JP2019515654 A JP 2019515654A JP 2019515654 A JP2019515654 A JP 2019515654A JP 2019532931 A5 JP2019532931 A5 JP 2019532931A5
Authority
JP
Japan
Prior art keywords
treatment
pharmaceutical composition
anterior
composition according
posterior blepharitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515654A
Other languages
English (en)
Japanese (ja)
Other versions
JP7012075B2 (ja
JP2019532931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073697 external-priority patent/WO2018054932A1/en
Publication of JP2019532931A publication Critical patent/JP2019532931A/ja
Publication of JP2019532931A5 publication Critical patent/JP2019532931A5/ja
Application granted granted Critical
Publication of JP7012075B2 publication Critical patent/JP7012075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515654A 2016-09-22 2017-09-20 眼瞼炎の治療に使用するための医薬組成物 Active JP7012075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16190138 2016-09-22
EP16190138.4 2016-09-22
PCT/EP2017/073697 WO2018054932A1 (en) 2016-09-22 2017-09-20 Pharmaceutical compositions for use in the therapy of blepharitis

Publications (3)

Publication Number Publication Date
JP2019532931A JP2019532931A (ja) 2019-11-14
JP2019532931A5 true JP2019532931A5 (cg-RX-API-DMAC7.html) 2020-11-05
JP7012075B2 JP7012075B2 (ja) 2022-01-27

Family

ID=56990295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515654A Active JP7012075B2 (ja) 2016-09-22 2017-09-20 眼瞼炎の治療に使用するための医薬組成物

Country Status (11)

Country Link
US (1) US11684589B2 (cg-RX-API-DMAC7.html)
EP (1) EP3515420B1 (cg-RX-API-DMAC7.html)
JP (1) JP7012075B2 (cg-RX-API-DMAC7.html)
KR (1) KR102614858B1 (cg-RX-API-DMAC7.html)
CN (2) CN109890374A (cg-RX-API-DMAC7.html)
AU (1) AU2017329772B2 (cg-RX-API-DMAC7.html)
CA (1) CA3036297C (cg-RX-API-DMAC7.html)
ES (1) ES2969758T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019003363A (cg-RX-API-DMAC7.html)
PL (1) PL3515420T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018054932A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
WO2014041071A1 (en) 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
EP3399962B1 (en) 2016-12-23 2020-06-10 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
BR112020017838A2 (pt) 2018-03-02 2020-12-22 Novaliq Gmbh Composições farmacêuticas que compreendem nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CA3111873A1 (en) * 2018-09-22 2020-03-26 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP4025235A1 (en) 2019-09-06 2022-07-13 Novaliq GmbH Ophthalmic composition for the treatment of uveitis
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (cg-RX-API-DMAC7.html) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
US6224887B1 (en) 1998-02-09 2001-05-01 Macrochem Corporation Antifungal nail lacquer and method using same
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE322889T1 (de) 1999-02-08 2006-04-15 Alza Corp Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
KR100757611B1 (ko) 2001-09-04 2007-09-10 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 손발톱 성장의 기능장애와 질환을 치료하기 위한 플라스터
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
MXPA06002163A (es) 2003-08-25 2006-05-22 Foamix Ltd Espuma farmaceutica de penetracion.
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
EP1684724A4 (en) 2003-11-19 2008-04-02 Barnes Jewish Hospital IMPROVED DRUG DELIVERY
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20080019926A1 (en) 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
US20050288197A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer topical eye compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
DE602006004887D1 (de) 2005-08-05 2009-03-05 Bharat Serums & Vaccines Ltd Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20080050335A1 (en) 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス,インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
AU2009228205A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
ES2377152T3 (es) 2008-04-18 2012-03-22 Novaliq Gmbh Uso inhalativo e instilativo de alcanos semifluorados como vehículos de principios activos en la región intrapulmonar
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
EP2367527A2 (en) 2008-11-26 2011-09-28 SurModics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
JP2013500239A (ja) 2009-07-24 2013-01-07 ミーカ ファルマ ゲゼルシャフト フュア ディー エントヴィックルング ウント フェアマルクトゥング ファルマツォイティッシャー プロドゥクテ ミット ベシュレンクテル ハフツング 活性剤を含む発泡可能な液体組成物およびその製造または開発方法
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
TR201901309T4 (tr) 2011-01-04 2019-02-21 Novaliq Gmbh Semiflorlanmış alkanları içeren o/w emülsiyonları.
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
MX361681B (es) 2012-01-23 2018-12-13 Novaliq Gmbh Composiciones de proteína estabilizadas basadas en alcanos semifluorados.
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
WO2014041071A1 (en) 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
AU2017275492A1 (en) 2016-06-01 2018-12-20 Harold Richard Hellstrom Treatment of dry eye disease with parasympathetic and anti-sympathetic agents
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
EP3518921B1 (en) 2016-09-28 2021-08-11 Novaliq GmbH Compositions comprising a cannabinoid receptor binding ligand
CA3045733C (en) 2016-12-22 2024-01-16 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
EP3399962B1 (en) 2016-12-23 2020-06-10 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3618782B1 (en) 2017-05-06 2021-05-26 Novaliq GmbH Drop dispenser
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
BR112020017838A2 (pt) 2018-03-02 2020-12-22 Novaliq Gmbh Composições farmacêuticas que compreendem nebivolol
US20210121471A1 (en) 2018-03-28 2021-04-29 Novaliq Gmbh Pharmaceutical compositions comprising timolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CA3111873A1 (en) 2018-09-22 2020-03-26 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
EP3886907B1 (en) 2018-11-27 2024-10-02 Novaliq GmbH Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
CN113518619A (zh) 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
CN114126580A (zh) 2019-05-24 2022-03-01 诺瓦利克有限责任公司 用于治疗眼部过敏的眼用组合物

Similar Documents

Publication Publication Date Title
JP2019532931A5 (cg-RX-API-DMAC7.html)
JP7012075B2 (ja) 眼瞼炎の治療に使用するための医薬組成物
Yang et al. Topical ocular drug delivery systems: Innovations for an unmet need
CA3045733A1 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP2020502197A5 (cg-RX-API-DMAC7.html)
JP2018529693A5 (cg-RX-API-DMAC7.html)
JP2019534867A5 (cg-RX-API-DMAC7.html)
UA113525C2 (xx) Спосіб лікування пресбіопії
JP2015509500A5 (cg-RX-API-DMAC7.html)
CN106999543B (zh) 包含环孢霉素和海藻糖的眼用组合物
Lazreg et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
IL275339B1 (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
JP7787129B2 (ja) 眼科組成物
Rocha et al. Eyelid margin disease (blepharitis and meibomian gland dysfunction): clinical review of evidence-based and emerging treatments
Shoji et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study
Bagnis et al. Antiglaucoma drugs: The role of preservative-free formulations
EP3474836B1 (en) Salbutamol-containing ophthalmic medicament
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
Ober et al. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection
WO2016046442A1 (es) Composición de doxiciclina en liposomas para la prevención, mejora y/o tratamiento de patologías oculares
Cornel et al. Novelties in medical treatment of glaucoma
JP5555693B2 (ja) 調節性眼精疲労の予防または治療に有用な化合物
Marshall et al. Dry Eye Disease: Focus on Prescription Therapy
ES2577885B1 (es) Composición de doxiciclina en liposomas para la prevención, mejora y/o tratamiento de patologías oculares.
Nowak et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia